Bruton’s tyrosine kinase (BTK) as a promising target in solid tumors

Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL

“…Ibrutinib was shown to have activity in several pre-clinical models of solid tumors such as pancreatic cancer [88], breast cancer [89] or lung cancer [90]. Ongoing clinical trials investigate the use of ibrutinib as an immunomodulator alone or in combination with PD-1/PD-L1 inhibitors in solid malignancies [91]. With better understanding of the behavior and function of T cells upon treatment with BTKi therapy, rationale immunotherapy-based combinations approaches could provide better disease control, shorten treatment duration and mitigate treatment-related toxicities associated with extended therapy.…”

N-Terminal Proteoforms in Human Disease

“…The cytoplasmic tyrosine-protein kinase BMX, or epithelial and endothelial tyrosine kinase (ETK), is a nonreceptor tyrosine kinase with functions in several cellular processes [25]. ETK/BMX regulates the activity of proteins such as PI3-AKT, TNFR2, PAK1, TP53, PIM, and STAT3, and has an important role in inflammation.…”

Ibrutinib Therapy for Chronic Lymphocytic Leukemia Complicated with Secondary Serous Adenocarcinoma of the Peritoneum

“…Secondly, there is increasing evidence from preclinical data indicating the role of BTK in progression of prostate, ovarian, gastric and breast cancer models and clinical trials assessing ibrutinib efficacy in several solid tumours are underway. 9,10 Taking this into consideration coadministration of ibrutinib with other cytostatic agents could potentially have additive anti-cancer International Journal of Hematology and Oncology and anti-leukemic effect and target both diseases. In this case combining ibrutinib for CLL and palliative cytotoxic chemotherapy for serous adenocrcinoma resulted rather safe and the patient survived for additional 2 years from the diagnosis of aggressive secondary tumour.…”